0.4865
price down icon3.79%   -0.0084
 
loading
Talphera Inc stock is traded at $0.4865, with a volume of 9,544. It is down -3.79% in the last 24 hours and down -14.00% over the past month. Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.4781
Open:
$0.49
24h Volume:
9,544
Relative Volume:
0.23
Market Cap:
$9.43M
Revenue:
$2.82M
Net Income/Loss:
$-14.20M
P/E Ratio:
-0.5724
EPS:
-0.85
Net Cash Flow:
$-15.13M
1W Performance:
-8.31%
1M Performance:
-14.00%
6M Performance:
-40.26%
1Y Performance:
-55.34%
1-Day Range:
Value
$0.4509
$0.51
1-Week Range:
Value
$0.4509
$0.512
52-Week Range:
Value
$0.45
$1.19

Talphera Inc Stock (TLPH) Company Profile

Name
Name
Talphera Inc
Name
Phone
650-216-3500
Name
Address
1850 GATEWAY DRIVE, SAN MATEO
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
TLPH's Discussions on Twitter

Compare TLPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
TLPH
Talphera Inc
0.46 10.29M 2.82M -14.20M -15.13M -0.85
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.13 50.54B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
170.84 74.02B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.8368 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.95 45.82B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.22 20.31B 16.54B -1.64B 749.00M -1.45

Talphera Inc Stock (TLPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-28-25 Initiated Rodman & Renshaw Buy
Jul-20-20 Downgrade Credit Suisse Neutral → Underperform
Nov-11-19 Downgrade Credit Suisse Outperform → Neutral
Aug-05-19 Resumed Credit Suisse Outperform
Jul-10-19 Resumed Credit Suisse Outperform
Apr-24-19 Resumed B. Riley FBR Buy
Feb-15-19 Initiated Credit Suisse Outperform
Oct-23-18 Initiated B. Riley FBR Buy
Oct-13-17 Downgrade Jefferies Buy → Hold
Oct-13-17 Reiterated RBC Capital Mkts Outperform
Jul-14-17 Resumed Jefferies Buy
Sep-15-16 Reiterated ROTH Capital Buy
Aug-05-16 Downgrade Stifel Buy → Hold
Oct-30-15 Upgrade Jefferies Hold → Buy
Oct-05-15 Reiterated ROTH Capital Buy
Sep-02-15 Initiated H.C. Wainwright Buy
Jul-10-15 Resumed ROTH Capital Buy
May-06-15 Reiterated Mizuho Neutral
May-05-15 Reiterated RBC Capital Mkts Outperform
Mar-10-15 Reiterated RBC Capital Mkts Outperform
Mar-09-15 Downgrade Mizuho Buy → Neutral
View All

Talphera Inc Stock (TLPH) Latest News

pulisher
May 29, 2025

Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World

May 29, 2025
pulisher
May 17, 2025

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN

May 17, 2025
pulisher
May 17, 2025

Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks

May 17, 2025
pulisher
May 15, 2025

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN

May 15, 2025
pulisher
May 15, 2025

Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks

May 15, 2025
pulisher
May 15, 2025

TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Talphera: Q1 Earnings Snapshot - Greenwich Time

May 15, 2025
pulisher
May 15, 2025

Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Talphera, Inc. Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Talphera Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025 - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

TLPH Reports Strong Q1 Revenue with Promising Study Progress | T - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Talphera Inc Reports Q1 2025 EPS Loss of $0.10, Beating Estimates; Revenue Details Unavailable - GuruFocus

May 14, 2025
pulisher
May 14, 2025

TALPHERA, INC. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

TLPH Reports Strong Q1 Revenue with Promising Study Progress | TLPH Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Talphera Announces First Quarter 2025 Financial Results and Prov - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Talphera Cuts Net Loss 32%, Secures FDA Approval for Streamlined Clinical Trial Design - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | TLPH Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Talphera reports Q1 EPS (10c), consensus (14c) - TipRanks

May 14, 2025
pulisher
May 14, 2025

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

May 14, 2025
pulisher
May 08, 2025

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune

May 08, 2025
pulisher
May 07, 2025

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus

May 07, 2025
pulisher
May 06, 2025

All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance

May 06, 2025
pulisher
Apr 05, 2025

HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Estimates Talphera FY2029 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Talphera: Q4 Earnings Snapshot - CT Insider

Apr 01, 2025
pulisher
Apr 01, 2025

Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Talphera Reports 2024 Financial Results and Study Update - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

TALPHERA, INC. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Talphera Inc Stock (TLPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Talphera Inc Stock (TLPH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Aslam Shakil
Chief Medical Officer
Jun 14 '24
Buy
1.07
5,000
5,357
37,695
Aslam Shakil
Chief Medical Officer
Jun 13 '24
Buy
0.98
695
681
32,695
Angotti Vincent J.
CHIEF EXECUTIVE OFFICER
Dec 05 '24
Buy
0.64
5,000
3,200
208,066
ASADORIAN RAFFI
Chief Financial Officer
Dec 02 '24
Sale
0.77
155
119
37,578
Angotti Vincent J.
CHIEF EXECUTIVE OFFICER
Nov 27 '24
Buy
0.73
5,000
3,650
203,066
$8.425
price down icon 3.28%
drug_manufacturers_specialty_generic RDY
$14.62
price down icon 0.81%
$124.86
price down icon 0.01%
drug_manufacturers_specialty_generic HCM
$14.21
price up icon 2.99%
$324.39
price down icon 0.70%
$17.16
price down icon 0.72%
Cap:     |  Volume (24h):